ClinicalTrials.gg
CompletedNCT01431521Updated Sep 10, 2018Results posted

Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)

A Phase 1 interventional study of MK-4074 200 mg and Placebo for MK-4074 in Non-alcoholic Fatty Liver Disease, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-09-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing pioglitazone in Non-alcoholic Fatty Liver Disease — 4 open to participants now, 4 under way, none of them phase 3. Pioglitazone · Non-alcoholic Fatty Liver Disease.

Enrollment
15th of 19
31 · median 96
Started
2011
the only one that year
Phase 1
Only one
of the 19
Registered
8th of 19
by date
Lead sponsor
1 of 19
Merck Sharp & Dohme LLC

Among the 19 studies testing pioglitazone in Non-alcoholic Fatty Liver Disease, this one is the 15th largest by enrollment, is the only one that started in 2011, is the only one in phase 1, and was the 8th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

4 of the 19 studies testing pioglitazone in Non-alcoholic Fatty Liver Disease are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing pioglitazone in Non-alcoholic Fatty Liver Disease, or all of them as a file.
02

Study summary

This study will evaluate changes in liver fat content following multiple oral doses of MK-4074 and Pioglitazone Hydrochloride in adult males and females with fatty liver disease. The primary hypothesis of the study is that a multiple-dose administration of MK-4074 200 mg twice daily for 4 weeks results in a decrease in hepatic fat content with respect to placebo in adult male and female participants with hepatic steatosis (i.e., on order of 50% reduction in hepatic fat with respect to placebo is expected).

03

Conditions studied

  • Non-alcoholic Fatty Liver Disease
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females must be of non-
  • (BMI) ≥32.0 kg/m\^2
  • In good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests
  • No abnormality on
  • Has documented hepatic fat content ≥10% within 6 months of enrollment
  • Maintained stable weight (by history) for at least 4 weeks
  • Agrees not to initiate a weight loss program and agrees to maintain consistent dietary habits and exercise routines for the duration of the study
  • Has a rating of 'moderate' or 'severe' steatosis on ultrasound at the prestudy (screening) visit

Exclusion criteria

Exclusion Criteria:

  • Change in weight greater than 4% between prestudy visit and randomization into the study
  • History of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the participant
  • Liver disease other than fatty liver or non-alcoholic steatohepatitis (NASH)
  • (ALT) or aspartate aminotransferase (AST) ≥3x the
  • Serum triglyceride level >600 mg/dL
  • History of stroke, chronic seizures, or major neurological disorder
  • History of endocrine, gastrointestinal, cardiovascular (including congestive heart failure), hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
  • Had abdominal surgery, gastric bypass, bowel resection, recent liver , or any other procedure within a minimum of 4 weeks
  • History of neoplastic disease
  • Claustrophobia or other to magnetic resonance imaging (MRI)
  • Have not washed off agents associated with changes in hepatic fat or used for treatment of Non-alcoholic fatty liver disease (NAFLD) or NASH for a minimum of 3 months prior
  • Consumes excessive amounts of alcohol, coffee, tea, cola, or other caffeinated beverages
  • Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another study within 4 weeks
  • Significant multiple and/or severe allergies
  • Intolerance or to pioglitazone hydrochloride or any inactive ingredients
  • Regular user of any illicit drugs or has a history of drug (including alcohol) abuse.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    MK-4074

    Participants will receive oral doses of MK-4074 200 mg (2 x 100-mg capsules) twice daily for 4 weeks.

    Drug: MK-4074 200 mg

  • Placebo comparator
    Placebo for MK-4074

    Participants will receive oral doses of placebo to match MK-4074 twice daily for 4 weeks.

    Drug: Placebo for MK-4074

  • Experimental
    Pioglitazone

    Participants will receive oral doses of pioglitazone hydrochloride 30 mg (1 x 30-mg tablet) once daily for 4 weeks.

    Drug: Pioglitazone hydrochloride 30 mg

  • Placebo comparator
    Placebo for pioglitazone

    Participants will receive oral doses of placebo to match pioglitazone hydrochloride once daily for 4 weeks.

    Drug: Placebo for pioglitazone hydrochloride

Interventions

  • DrugMK-4074 200 mg

    2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks

  • DrugPlacebo for MK-4074

    2 x 100-mg capsules, orally, BID for 4 weeks.

  • 1 x 30-mg tablet, orally, once daily for 4 weeks

  • DrugPlacebo for pioglitazone hydrochloride

    1 x 30-mg tablet, orally, once daily for 4 weeks

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Hepatic Fat

    Hepatic fat content was assessed via magnetic resonance imaging (MRI) prior to first dose administration and following 4 weeks of treatment. Percent change in hepatic fat fraction from baseline was calculated for each of the 9 liver regions separately and then these were averaged to calculate overall percent change from baseline for each participant.

    Time frame: Baseline and Week 4

  2. Number of Participants Experiencing One or More Adverse Events (AE)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 10 weeks

  3. Number of Participants Who Discontinued Study Drug Due to an AE

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 4 weeks

Secondary outcomes

  1. Percent Change From Baseline in Alanine Transaminase (ALT)

    Hepatic steatosis is not uncommonly associated with mild elevations in serum transaminases, specifically ALT, and these elevations may be a marker of more advanced hepatic disease. Serum transaminases were monitored at baseline and once weekly for the duration of the study to permit a better understanding of the time course of potential improvement in hepatic inflammation during the course of this short study.

    Time frame: Baseline and Week 4

  2. Percent Change From Baseline Aspartate Transaminase (AST)

    Hepatic steatosis is not uncommonly associated with mild elevations in serum transaminases, including AST, and these elevations may be a marker of more advanced hepatic disease. Serum transaminases were monitored at baseline and once weekly for the duration of the study to permit a better understanding of the time course of potential improvement in hepatic inflammation during the course of this short study.

    Time frame: Baseline and Week 4

07

Results

Posted Mar 25, 2016

Participant flow

Thirty-one male or female participants (non-childbearing potential) between the ages of 18 and 60, inclusive, with body mass index (BMI) ≥ 32 kg/m\^2 were enrolled in the study. Participants were pre-screened by means of ultrasound, and only those participants with a rating of "moderate" or "severe" steatosis were further evaluated by means of MRI.

Participant flow — Overall Study
MilestoneMK-4074Placebo for MK-4074PioglitazonePlacebo for Pioglitazone
Started105115
Treated105105
Completed105105
Not completed0010
Withdrew: Withdrawal by subject0010

Outcome measures

PrimaryPercent Change From Baseline in Hepatic Fat

Hepatic fat content was assessed via magnetic resonance imaging (MRI) prior to first dose administration and following 4 weeks of treatment. Percent change in hepatic fat fraction from baseline was calculated for each of the 9 liver regions separately and then these were averaged to calculate overall percent change from baseline for each participant.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Hepatic Fat
Percent changeMK-4074PioglitazonePlacebo
Percent Change From Baseline in Hepatic Fat-35.73 (-44.53 to -26.93)-18.04 (-26.84 to -9.24)8.63 (-0.17 to 17.43)
Statistical analysis
  • MK-4074 vs Placebo · Linear mixed effects model · p = <0.001 · Least squares mean difference: -44.37 · 95% CI -54.67 to -34.07Treatment as fixed factor and predose Day 1 value, as a fixed covariate
  • Pioglitazone vs Placebo · Linear mixed effects model · p = <0.001 · Least squares mean difference: -26.67 · 95% CI -36.97 to -16.37Treatment as fixed factor and predose Day 1 value, as a fixed covariate
  • MK-4074 vs Pioglitazone · Linear mixed effects model · p = 0.007 · Least squares mean difference: -17.69 · 95% CI -36.97 to -7.39Treatment as fixed factor and predose Day 1 value, as a fixed covariate
SecondaryPercent Change From Baseline in Alanine Transaminase (ALT)

Hepatic steatosis is not uncommonly associated with mild elevations in serum transaminases, specifically ALT, and these elevations may be a marker of more advanced hepatic disease. Serum transaminases were monitored at baseline and once weekly for the duration of the study to permit a better understanding of the time course of potential improvement in hepatic inflammation during the course of this short study.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Alanine Transaminase (ALT)
Percent changeMK-4074PioglitazonePlacebo
Percent Change From Baseline in Alanine Transaminase (ALT)-9.82 (-21.13 to 1.49)-20.21 (-31.52 to -8.90)-3.47 (-15.08 to 8.13)
Statistical analysis
  • MK-4074 vs Placebo · Linear mixed effect model · p = >0.200 · Least square mean difference: -6.35 · 95% CI -18.69 to 6.00Containing fixed effects for treatment, and predose Day 1 (baseline) as a fixed covariate
  • Pioglitazone vs Placebo · Linear mixed effects model · p = 0.028 · Least squares mean difference: -16.74 · 95% CI -29.08 to -4.40Containing fixed effects for treatment, and predose Day 1 (baseline) as a fixed covariate
SecondaryPercent Change From Baseline Aspartate Transaminase (AST)

Hepatic steatosis is not uncommonly associated with mild elevations in serum transaminases, including AST, and these elevations may be a marker of more advanced hepatic disease. Serum transaminases were monitored at baseline and once weekly for the duration of the study to permit a better understanding of the time course of potential improvement in hepatic inflammation during the course of this short study.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percent change
Percent Change From Baseline Aspartate Transaminase (AST)
Percent changeMK-4074PioglitazonePlacebo
Percent Change From Baseline Aspartate Transaminase (AST)-6.74 (-19.73 to 6.24)-13.95 (-26.93 to -0.97)-3.28 (-16.64 to 10.08)
Statistical analysis
  • MK-4074 vs Placebo · Linear mixed effects model · p = >0.200 · Least squares mean difference: -3.47 · 95% CI -17.85 to 10.92Containing fixed effects for treatment, and predose Day 1 (baseline) as a fixed covariate
  • Pioglitazone vs Placebo · Linear mixed effects model · p = >0.200 · Least squares mean difference: -10.67 · 95% CI -25.06 to 3.71Containing fixed effects for treatment, and predose Day 1 (baseline) as a fixed covariate
PrimaryNumber of Participants Experiencing One or More Adverse Events (AE)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 10 weeks
Reported as:
Number · Participants
Number of Participants Experiencing One or More Adverse Events (AE)
ParticipantsMK-4074PioglitazonePlacebo
Number of Participants Experiencing One or More Adverse Events (AE)445
PrimaryNumber of Participants Who Discontinued Study Drug Due to an AE

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 4 weeks
Reported as:
Number · Participants
Number of Participants Who Discontinued Study Drug Due to an AE
ParticipantsMK-4074PioglitazonePlacebo
Number of Participants Who Discontinued Study Drug Due to an AE000

Adverse events

Collected over Up to 10 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-4074—0/10 (0%)4/10 (40%)
Placebo for MK-4074—0/5 (0%)1/5 (20%)
Pioglitazone—0/10 (0%)4/10 (40%)
Placebo for Pioglitazone—0/5 (0%)4/5 (80%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventMK-4074Placebo for MK-4074PioglitazonePlacebo for Pioglitazone
Upper respiratory tract infectionInfections and infestations2/100/50/101/5
Accidental overdoseInjury, poisoning and procedural complications0/100/50/101/5
Back painMusculoskeletal and connective tissue disorders0/101/51/100/5
DizzinessNervous system disorders0/100/51/101/5
HeadacheNervous system disorders1/100/52/101/5
MigraineNervous system disorders0/101/50/100/5
AnxietyPsychiatric disorders0/100/50/101/5
PruritusSkin and subcutaneous tissue disorders0/101/50/100/5
Iron deficiency anaemiaBlood and lymphatic system disorders0/100/50/101/5
Eyelids pruritusEye disorders0/100/50/101/5

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MK-4074Placebo for MK-4074PioglitazonePlacebo for PioglitazoneTotal
Mean35.1 ± 5.848.0 ± 7.643.7 ± 12.147.8 ± 10.642.3 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)MK-4074Placebo for MK-4074PioglitazonePlacebo for PioglitazoneTotal
Female01247
Male1049124
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2011 to primary completion in Sep 2012, 10 months.

Results were first posted in Mar 2016, 3 years 6 months after primary completion.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 10 months is close to that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2011
First posted
Sep 9, 2011
StartActual
Oct 26, 2011
Primary completionActual
Sep 18, 2012
CompletionActual
Oct 1, 2012
Results first posted
Mar 25, 2016
Last update
Sep 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01431521
Responsible party
Sponsor
First posted
Sep 9, 2011
Start date
Oct 26, 2011
Primary completion
Sep 18, 2012
Completion
Oct 1, 2012
Results posted
Mar 25, 2016
Last update
Sep 10, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pioglitazone

Start the discussion